Blood: Daremu mono-anti-combined CyBorD therapy newly diagnosed AL amyloid

Although treatments for light-stranded (AL) amyloid have not yet been approved, cyclophosphamide, boratiandami and CyBorD are considered standard treatments for newly diagnosed patientsBased on the safety and efficacy of anti-CD38 antibody daratumumab (Daremu monoantigen) in multiple myeloma (MM), the phase 3 ANDROMEDA study compared the efficacy of Darremu mono-resistance-CyBorD and CyBorD treatment for newly diagnosed AL amyloidthis paper reported the safety trial results of 28 patientsdaremu monoantigen: subcutaneous injection (DARA SC), first two courses (28 days/course), once a week (QW); 3-6 courses, twice a week (Q2W); 7 course-2 years, four times a week (Q4W)CyBorD administration: weekly administration, 4 weeks/course of treatment, 6 consecutive coursesthe median age of the patients in the test was 67.5 years, the median time from diagnosis to the enlistment trial was 59.5 days, and the median number of organs affected was 2; The median treatment was 16the most common adverse reactions requiring emergency treatment were diarrhea (68%), fatigue (54%) and peripheral edema (50%), consistent with the safety of MM and CyBorD treated with DARA SC11 patients had injection-related reactionsNo adverse reactions associated with stage 5 treatment; 5 patients died and 3 patients underwent an autonomous stem cell transplantoverall remission rate of 96%, 23 (82%) of patients received very good partial remission, 15 (54%) patients received full remission, and 20, 22 and 17 patients received at least partial remission in the first, 3 and 6 months, respectivelyThe organ remission rate was 64% (17.6 months of median follow-up)At the third, sixth and 12 months, 6/16, 7/15 and 10/15 patients received renal remission, and 6/16, 6/13 and 8/13 patients received cardiovascular remission, respectivelyIn addition, at 12 months, two of the three patients with liver relapse received liver remissionDaratumumab-CyBorD has good tolerance, no new safety problems compared to intravenous administration, and shows higher blood and organ remission rates